-
Innovation Ranking
Innovation Ranking – Theravance Biopharma Inc
Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease and gastroparesis and concurrent bacteremia. Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ampreloxetine Hydrochloride in Orthostatic Hypotension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ampreloxetine Hydrochloride in Orthostatic Hypotension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ampreloxetine Hydrochloride in Orthostatic Hypotension Drug Details: Ampreloxetine HCL (TD-9855) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izorlisib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izorlisib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Izorlisib in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ieramilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ieramilimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ieramilimab in Solid Tumor Drug Details: Ieramilimab (LAG-525) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NX-2127 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NX-2127 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NX-2127 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Company Insights
Innovation and Patenting activity of Theravance Biopharma Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Theravance Biopharma Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Hypotension – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypotension - Drugs In Development, 2023’, provides an overview of the Hypotension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypotension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Celiac Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Celiac Disease - Drugs In Development, 2023’, provides an overview of the Celiac Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...